Bayer Intellectual Property Gmbh

Bayer Pharma Aktiengesellschaft

Oklahoma Medical Research Foundation

Aronora Inc.

Andreas Wilmen

Mark Jean Gnoth

Christoph Freiberg

Niels Svenstrup

Ulrich Rester

Stephan Siegel

Anja Buchmüller

Erik Tucker

Mark Trautwein

Adrian Tersteegen

Susanne Röhrig

Christoph Gerdes

Martina Schäfer

Stefan Heitmeier

Simone Greven

Michael Strerath

Frank Dittmer

Joanna Grudzinska-Goebel

Lars Linden

Axel Harrenga

Philberta Y Leung

Ricarda Finnern

Asako Itakura

Christiane Otto

Hannah Jörißen

Julia Straßburger

Michael Sperzel

Dmitry Zubov

Michael Gerisch

Andrea Eicker

Sandra Bruder

Siegmund Wolf

Jochen Strayle

Hanna Tinel

Julia Straβburger

Xiao-Yan Zhao

Ulrich Haupts

Ji-Yun Kim

Julia Strassburger

Hannah Jöriβen

Kirsten Leineweber

Subramanian Yegneswaran

Hannah Jörissen

Karin Regnstrom

Ursula Egner

Xinquan Wang

Nina Alexandra Scheerer

Martina Schafer

Anja Buchmuller

Hannah Jorissen

Jochen Stayle

Provided are optimized humanized antibodies that selectively bind to and inhibit activated protein C without binding to or inhibiting unactivated protein C. In particular, the antibodies bind to particular epitopes outside the catalytic triad of the active site of human activated protein C. Methods of treatment employing these antibodies are described herein.

Epitope of optimized humanized monoclonal antibodies against activated protein C and uses thereof

The present invention relates to antibodies capable of binding to the coagulation Factor XI and/or its activated form factor XIa and methods of use thereof, particularly methods of use as agents inhibiting platelet aggregation and by this inhibits thrombus formation.

Antibodies capable of binding to the coagulation factor XIa and uses thereof

The present invention in general relates to novel binding molecules, in particular antibodies and compositions and kits comprising the same. Said binding molecules are capable of binding to human Factor XI and hence envisaged to be particularly useful in inhibiting thrombosis without compromising hemostasis. The binding molecules, compositions and kits provided herein are therefore inter alia intended for treatment of thrombosis-related diseases and conditions. Moreover, polynucleotides encoding the binding molecules of the invention, vectors comprising said polynucleotides and host cells for producing the polynucleotides are provided herein.

Antibodies against factor XI and uses thereof

Nucleic acids and host cells expressing antibodies capable of binding to the coagulation factor XIa and uses thereof

Antibodies capable of binding to the coagulation Factor XI and/or its activated form factor Xia and uses thereof

The present invention is directed to the neutralizing prolactin receptor antibody Mat3, and antigen binding fragments, pharmaceutical compositions containing them and their use in the treatment or prevention of benign disorders and indications mediated by the prolactin receptor such as endometriosis, adenomyosis, non-hormonal female contraception, benign breast disease and mastalgia, lactation inhibition, benign prostate hyperplasia, fibroids, hyper- and normoprolactinemic hair loss, and cotreatment in combined hormone therapy to inhibit mammary epithelial cell proliferation and for the treatment and prevention of antiestrogen-resistant breast cancer. The antibody of the invention blocks prolactin receptor-mediated signalling.

Neutralizing prolactin receptor antibody Mat3 and its therapeutic use

The present invention is directed to the neutralizing prolactin receptor antibody 006-H08, as well as maturated forms thereof, and antigen-binding fragments, pharmaceutical compositions containing them and their use in the treatment or prevention of benign disorders and indications mediated by the prolactin receptor such as endometriosis, adenomyosis, non-hormonal female contraception, benign breast disease and mastalgia, lactation inhibition, benign prostate hyperplasia, fibroids, hyper- and normoprolactinemic hair loss, and cotreatment in combined hormone therapy to inhibit mammary epithelial cell proliferation. The antibodies of the invention block prolactin receptor-mediated signaling.

Neutralizing prolactin receptor antibodies and their therapeutic use

The invention relates to substituted imidazo-, pyrazolopyrazines and imidazotriazines and processes for their preparation, and their use for the manufacture of medicaments for the treatment and/or prophylaxis of diseases, in particular of hematological disorders, preferably of leukopenias and neutropenias.

Imidazo-, pyrazolopyrazines and imidazotriazines and their use

The present invention provides Relaxin fusion polypeptides A-L-B with a non-wild type array of the Relaxin A-chain and Relaxin B-chain, wherein the A- and B-chains are connected by a linker peptide. The invention further provides Relaxin fusion polypeptides with extended half-life. Furthermore, the invention provides nucleic acid sequences encoding the foregoing fusion polypeptides, vectors containing the same, pharmaceutical compositions and medical use of such fusion polypeptides.

Relaxin fusion polypeptides and uses thereof

The neutralizing prolactin receptor antibody Mat3, and antigen binding fragments, pharmaceutical compositions containing them and their use in the treatment or prevention of benign disorders and indications mediated by the prolactin receptor such as endometriosis, adenomyosis, non-hormonal female contraception, benign breast disease and mastalgia, lactation inhibition, benign prostate hyperplasia, fibroids, hyper- and normoprolactinemic hair loss, and cotreatment in combined hormone therapy to inhibit mammary epithelial cell proliferation and for the treatment and prevention of antiestrogen-resistant breast cancer. The antibody blocks prolactin receptor-mediated signalling.

The present invention is directed to the neutralizing prolactin receptor antibody 005-C04, as well as maturated forms thereof, and antigen binding fragments, pharmaceutical compositions containing them and their use in the treatment or prevention of benign disorders and indications mediated by the prolactin receptor such as endometriosis, adenomyosis, non-hormonal female contraception, benign breast disease and mastalgia, lactation inhibition, benign prostate hyperplasia, fibroids, hyper- and normoprolactinemic hair loss, and cotreatment in combined hormone therapy to inhibit mammary epithelial cell proliferation. The antibodies of the invention block prolactin receptor-mediated signaling.

The invention relates to substituted imidazo- and triazolopyrimidines and processes for their preparation, and their use for the manufacture of medicaments for the treatment and/or prophylaxis of diseases, in particular of haematological disorders, preferably of leucopenias and neutropenias.

Substituted imidazopyrimidines and triazolopyrimidines

The invention relates to substituted pyridines and to processes for preparation thereof, and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially of haematological disorders, preferably of leukopenia and neutropenia.

Substituted pyridines, and use thereof as GSK3 inhibitors

Growing community of inventors

Kö'ln, Germany

Andreas Wilmen